Investigating Exosomes in Pancreatic Cancer Progression
Role of Exosomes in Pancreatic Cancer Progression
This study is trying to find out if certain markers in the blood and urine of pancreatic cancer patients can help us understand how the disease progresses and identify new ways to diagnose it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06777030 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to identify circulating markers in the blood and urine of patients with pancreatic cancer and their association with disease stage. It will involve a cross-sectional analysis of tumor tissue, blood, and urine samples to characterize the content of extracellular vesicles/exosomes. The study will also explore the mechanisms of epithelial-mesenchymal transition and tumor aggressiveness to find potential predictive and diagnostic markers for pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with pancreatic cancer.
Not a fit: Patients who cannot undergo endoscopy with biopsy sampling or have other active neoplastic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of new diagnostic markers for early detection of pancreatic cancer.
How similar studies have performed: While this approach is exploratory, similar studies investigating exosomes in cancer have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * People with pancreatic cancer * 18 years old * Obtaining informed consent. Exclusion criteria: * Patients who do not need or cannot perform endoscopy with biopsy sampling; * patients with a previous or active neoplastic pathology, different from pancreatic neoplasia.
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Principal investigator: Leonardo Henry Umberto Eusebi, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Leonardo Henry Umberto Eusebi, MD
- Email: leonardo.eusebi@unibo.it
- Phone: 0039 0512143338
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.